184 related articles for article (PubMed ID: 28881711)
1. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Weisberg EL; Puissant A; Stone R; Sattler M; Buhrlage SJ; Yang J; Manley PW; Meng C; Buonopane M; Daley JF; Lazo S; Wright R; Weinstock DM; Christie AL; Stegmaier K; Griffin JD
Oncotarget; 2017 Aug; 8(32):52026-52044. PubMed ID: 28881711
[TBL] [Abstract][Full Text] [Related]
2. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
Aikawa T; Togashi N; Iwanaga K; Okada H; Nishiya Y; Inoue S; Levis MJ; Isoyama T
Oncotarget; 2020 Mar; 11(11):943-955. PubMed ID: 32215183
[No Abstract] [Full Text] [Related]
3. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
Weisberg E; Sattler M; Manley PW; Griffin JD
Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
Katayama K; Noguchi K; Sugimoto Y
Oncotarget; 2018 Sep; 9(76):34240-34258. PubMed ID: 30344940
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
7. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Yang J; Meng C; Weisberg E; Case A; Lamberto I; Magin RS; Adamia S; Wang J; Gray N; Liu S; Stone R; Sattler M; Buhrlage S; Griffin JD
Br J Cancer; 2020 Apr; 122(8):1175-1184. PubMed ID: 32015510
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM; Lazarus HM
J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
[TBL] [Abstract][Full Text] [Related]
11. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
12. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
[TBL] [Abstract][Full Text] [Related]
14. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Gallogly MM; Lazarus HM; Cooper BW
Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
[TBL] [Abstract][Full Text] [Related]
16. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
Yamatani K; Ai T; Saito K; Suzuki K; Hori A; Kinjo S; Ikeo K; Ruvolo V; Zhang W; Mak PY; Kaczkowski B; Harada H; Katayama K; Sugimoto Y; Myslinski J; Hato T; Miida T; Konopleva M; Hayashizaki Y; Carter BZ; Tabe Y; Andreeff M
Transl Oncol; 2022 Apr; 18():101354. PubMed ID: 35114569
[TBL] [Abstract][Full Text] [Related]
18. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.
Rosenberg MW; Watanabe-Smith K; Tyner JW; Tognon CE; Druker BJ; Borate U
Oncotarget; 2020 Jul; 11(29):2807-2818. PubMed ID: 32754299
[TBL] [Abstract][Full Text] [Related]
19. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
Green AS; Maciel TT; Hospital MA; Yin C; Mazed F; Townsend EC; Pilorge S; Lambert M; Paubelle E; Jacquel A; Zylbersztejn F; Decroocq J; Poulain L; Sujobert P; Jacque N; Adam K; So JC; Kosmider O; Auberger P; Hermine O; Weinstock DM; Lacombe C; Mayeux P; Vanasse GJ; Leung AY; Moura IC; Bouscary D; Tamburini J
Sci Adv; 2015 Sep; 1(8):e1500221. PubMed ID: 26601252
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Tvedt TH; Nepstad I; Bruserud Ø
Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]